Longitudinal Analysis Of Serum Neurofilament Light Chain: A Potential Therapeutic Monitoring Biomarker For Multiple Sclerosis
Hyun JW, Kim Y, Kim G, Kim SH and Kim HJ.
Mult Scler. 2019 Mar 26:1352458519840757
Serum neurofilament light chain (sNfL) has been proposed a potential biomarker in multiple sclerosis (MS) based on mainly cross-sectional observations in Western population. To clarify clinical implication of sNfL, we longitudinally analysed sNfL levels at multipletime points in Korean MS patients undergoing alemtuzumab therapy.
Between 2016 and 2018, 144 sera from 17 MS patients treated with alemtuzumab at National Cancer Centre and 35 sera from 35 age- and gender-matched healthy controls (HCs) were collected for a longitudinal study with a mean 21-month follow-up. The sera were measured for sNfL levels using single molecule array. Patients were classified into two groups: evidence of disease activity (EDA) or no evidence of disease activity (NEDA).
During alemtuzumab therapy, sNfL levels in EDA patients were significantly higher than those in NEDA patients and HCs ( p < 0.001). In longitudinal analysis, the sNfL levels were consistently low in NEDA patients, while it consistently increased in radiologically and/or clinically active status in EDA patients. All sNfL levels in radiologically and/or clinically active status samples were higher than those in inactive status samples.
These results suggest that sNfL is a promising monitoring biomarker for personalized therapeutics in MS patients.
Share this page